Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

No patients discontinued gedatolisib due to a treatment-related AE. One (2.3%) patient experienced Grade 3 hyperglycemia. “The 43% ORR reported in patients who received at least three prior lines of ...

Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing.

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary - The oncology landscape is being pulled ...

Notably, prior to the appointments of Kelly and Aromando, Oncolytics presented new GOBLET data at the 2025 ASCO Annual ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Baystreet.ca News Commentary – The current landscape of oncology is a mixed bag of results, with optimism coming from a ...

Amgen (AMGN) announced on Monday that a late-stage study evaluating its Bemarituzumab in combination with chemotherapy met ...

This session focused on the evolving treatment landscape for ER-positive, HER2-negative metastatic breast cancer, with particular attention to the use of oral endocrine therapies targeting ESR1 ...